Parkinson, J. T., Foley, É. M., Jadon, D. R., & Khandaker, G. M. (2020). Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management. *Therapeutic advances in musculoskeletal disease, 12.* https://doi.org/10.1177/1759720X20970028

Publisher's PDF, also known as Version of record

License (if available): CC BY

Link to published version (if available): 10.1177/1759720X20970028

Link to publication record in Explore Bristol Research

PDF-document

This is the final published version of the article (version of record). It first appeared online via Sage Publications at https://doi.org/10.1177/1759720X20970028. Please refer to any applicable terms of use of the publisher.
Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management

Joel T. Parkinson, Éimear M. Foley, Deepak R. Jadon and Golam M. Khandaker

Abstract: Depression is a major neuropsychiatric disorder common in patients with rheumatological conditions including spondyloarthritis (SpA). It is associated with higher disease activity, functional impairment, poor treatment response and quality of life in patients with musculoskeletal disorders. Using ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as examples, we have reviewed the evidence regarding the burden, risk factors, potential mechanisms and clinical management of depression in spondyloarthritis. The prevalence of depression is higher in patients with AS and PsA compared with the general population, with evidence of moderate/severe depression in about 15% of patients with AS or PsA. Mild depression is even more common and estimated to be present in about 40% of patients with AS. In addition to conventional risk factors such as stressful life events and socioeconomic deprivation, increased risk of depression in SpA may be associated with disease-related factors, such as disease activity, poor quality of life, fatigue, and sleep disturbances. Emerging evidence implicates inflammation in the aetiology of depression, which could also be a shared mechanism for depression and chronic inflammatory conditions such as AS and PsA. It is imperative for clinicians to actively assess and treat depression in SpA, as this could improve treatment adherence, quality of life, and overall long-term clinical and occupational outcomes. The use of validated tools can aid recognition and management of depression in rheumatology clinics. Management of depression in SpA, especially when to refer to specialist mental health services, are discussed.

Keywords: ankylosing spondylitis, assessment, depression, depressive disorder, epidemiology, psoriatic arthritis, spondyloarthritis, treatment

Received: 28 August 2020; revised manuscript accepted: 12 October 2020.

Introduction
Spondyloarthritis (SpA) is a group of chronic auto-inflammatory diseases characterised by peripheral and/or axial inflammation. Ankylosing spondylitis (AS) is characterised by axial inflammation and is the archetypal and most common type of spondyloarthritis, with regional prevalence ranging from 0.02–0.35%. Psoriatic arthritis (PsA), on the other hand, is characterised predominantly by peripheral inflammation. Prevalence of PsA remains largely unknown due to lack of data from some regions and due to differing classifications, but current estimates are about 0.02–0.25%. Though distinct, both diseases share common pathological features, with inflammation playing a crucial role. For instance, HLA-B27 gene polymorphisms are implicated in various spondyloarthritides. HLA-B27 is associated with spinal involvement, which may explain its strong association with AS, where it accounts for about 30% of heritability of the illness. Similarly, dysregulation of interleukin 17/23 pathway is implicated in the pathogenesis of both AS and PsA. Other implicated inflammatory cytokines include tumour necrosis factor alpha (TNF-α), IL-6 and IL-22. Such pathophysiologic similarity is reflected in common clinical features. For example, psychiatric symptoms...
Disorders, especially depression, are common in both AS and PsA, which may be linked with potential shared mechanisms such as inflammation.

Depression is a common and serious mental disorder that affects about 10–20% of the population in the lifetime, with a quarter of these cases beginning before age 20 years. It is one of the leading contributors of disability-adjusted life-years globally. Depressive symptoms can be broadly grouped as somatic or psychological. Somatic symptoms include fatigue, sleep disturbance, changes in appetite/weight, psychomotor agitation/retardation, and anhedonia (loss of pleasure). Psychological symptoms can include hopelessness, low self-esteem, excessive/inappropriate guilt and suicidality. Typically, depressive symptoms have a relapsing remitting nature, with high recurrence rate; up to 50% after the first episode and up to 90% after the third episode. Similar to most chronic illnesses of adult life, depression is a multifactorial condition with contributions from both genetic and environmental factors.

Recent genome-wide association studies have identified over 100 genetic variants associated with depression. These include genetic variants linked to specific brain regions such as the prefrontal cortex (SORCS3 on chromosome 10 and NEGR1 on chromosome 1), and neuro-transmission/signalling involving calcium (CACNA1E and CACNA2D1), dopamine (DRD2), and glutamate (GRIK5 and GRM5). The majority of genes identified were in the extended major histocompatibility complex (MHC) region, a region that is essential for autoimmunity. The cumulative effect of these variants on risk is relatively modest, with common single nucleotide polymorphisms (SNPs) contributing about 9% variation in depression liability. Notable environmental risk factors include stressful life events and early-life adversity such as abuse/maltreatment.

Pathophysiologic explanation and pharmacotherapy for depression is predicated on monoamine neurotransmitters, particularly serotonin. However, about a third of patients with depression do not respond to monoaminergic treatment such as selective serotonin reuptake inhibitors (SSRIs), suggesting other mechanisms contribute to illness risk. Emerging evidence indicates a potentially causal role for inflammation in the pathogenesis of depression. Depression is often comorbid with physical illnesses, notably cardiovascular disease and auto-immune/auto-inflammatory conditions such as arthritis. Inflammation could be a shared mechanism for depression and cardiovascular and possibly other comorbid physical illnesses such as type 2 diabetes.

Depression is a clinically relevant issue for rheumatologists as depressive symptoms are present in over a third of patients with rheumatological conditions, including rheumatoid arthritis (RA), axial spondyloarthritis and PsA. Depression is associated with poor adherence to treatment for chronic physical illness. Persistent depressive symptoms have been reported to not only exacerbate disease activity and disability but also potentially reduce treatment response. As a result, treating depression alone can improve rheumatological outcomes.

In this review, we discuss the current literature regarding the burden of depression in spondyloarthritis using AS and PsA as examples. We discuss prevalence, incidence, risk factors and potential mechanisms for the higher risk of depression in patients with AS and PsA. We review the current guidance on the management of depression as relevant to rheumatology clinicians.

Prevalence and incidence of depression in patients with AS or PsA
Depression is common in patients with rheumatological conditions including SpA with evidence for a complex bi-directional relationship. For instance, depression may exacerbate disease activity in patients with AS or PsA, while disease severity and certain symptoms can contribute to low mood. A Swedish population-based study reported that individuals with rheumatological disease had a higher risk of psychiatric disorders than the general population, with incidence rates showing an increase of 48.2 men per 100,000, and 45 women per 100,000. Those with AS or systemic lupus erythematosus (SLE) had a higher risk of subsequent psychiatric disorder(s) compared with patients with RA, while depression was the leading cause for psychiatric hospitalisation in patients with AS. However, this study examined severe psychiatric illness requiring hospitalisation as the outcome, and so may not reflect the burden of less severe psychiatric morbidity. A more recent study of comorbidities in axial spondyloarthritis (axSpA) used clinical information from clinical notes, and primary and secondary medical records to investigate a broader spectrum of comorbidities, not limited to hospitalisation or psychiatric illness. Depression was reported to be
one of the most common comorbidities in axSpA, present in about 15% of patients. Using hierarchical clustering of 38 conditions in 419 patients with axSpA the study identified 15 clusters. The depression-anxiety group was one of the most prevalent clusters, with patients in this group scoring higher on disease activity and lower on quality of life measures.

Three systematic literature reviews and meta-analyses on the prevalence of depression in AS and PsA are reported. The largest meta-analysis included 19,263 patients with AS from 33 studies conducted in Europe, Asia and South America. These studies measured depression using a variety of methods including self-report, validated questionnaires, clinical interviews, administrative and hospital records. In one meta-analysis, the pooled prevalence of depression in AS was reported to be 29%. However, findings from this meta-analysis were largely driven by one large study from Taiwan comprising 11,701 patients, which used the Elixhauser comorbidity index to record ICD-9 identified diagnoses of depression, rather than direct assessment of mood using a validated scale/interview. Reliance on clinical diagnosis can lack temporal validity, provides no information on current symptom severity, and may underestimate prevalence due to subthreshold and undiagnosed depression.

Although another meta-analysis comprised fewer studies, the assessment of depression was more robust due to the inclusion criteria that studies must use a validated diagnostic and screening criteria for depression, with a defined threshold. It included 14 studies of AS and two studies of non-radiographic axial SpA (nr-axSpA), totalling 4753 participants across all studies. Participants were recruited mainly from hospital settings such as rheumatology clinics, assessing depression using the well-validated Hospital Anxiety and Depression Scale (HADS). In individual studies included in this meta-analysis, the prevalence of depression ranged from 11% to 64% depending on the criteria and threshold used. According to this meta-analysis, pooled prevalence of mild depressive symptoms in patients with AS, axSpA and nr-axSpA was 38%, and that for moderate/severe depression (defined as HADS score ≥11) was 15%. The prevalence of depression was similar between AS, axSpA and nr-axSpA cohorts. Patients with depression had significantly worse SpA disease activity and greater SpA-related functional impairment. Younger age was associated with higher prevalence of depression. It is unclear why age was inversely correlated with risk of depression; however, it can be speculated that earlier onset rheumatological disease may cause a greater psychological burden due to increased severity and perceived impact on activity/functioning compared with healthy young peers. The majority of included studies recruited participants from hospital settings, which may result in higher SpA disease activity and functional impairment than primary care samples. This could contribute to a higher prevalence of depression in these cohorts. However, the authors state that there was no correlation between disease activity and depression prevalence estimates and suggest other confounders such as smoking and deprivation could account for the higher disease activity and functional impairment in depressed groups.

There are relatively fewer studies of the prevalence of depression in patients with PsA. A recent meta-analysis on this topic included three studies that collected participants from hospital settings such as outpatient facilities, rheumatology and dermatology clinics across South America, Europe, Canada, and Asia-Pacific, including a total of 1141 patients with PsA. Prevalence of moderate depression, assessed by HADS or the patient health questionnaire-9 (PHQ-9) criteria, across these studies ranged from 9% to 22%, with a pooled prevalence of 15% [95% confidence interval (CI), 9–21%], which is similar to prevalence of moderate depression in AS. However, these studies did not report prevalence for mild mood disorders in PsA. There is evidence that depression and anxiety is greater in PsA compared with psoriasis without arthritis, suggesting that risk for mood disorders could be associated with disease-related factors. Interestingly, depression has been reported to increase the risk of PsA in people with psoriasis. In a study using 25-years of primary care medical records, 73,447 patients with psoriasis were identified. Diagnosis of major depressive disorder (MDD) was reported to increase the risk of developing PsA by 37%, even when controlling for multiple covariates (hazard ratio 1.37; 95% CI, 1.05–1.80). In another longitudinal study of PsA, pain was associated with subsequent development of depression and vice versa.

With regards to incidence of depression in patients with AS and PsA, two recent systematic literature review and meta-analyses compared incidence of depression in these patient groups with that in...
Comprising 5947 patients with AS from three studies conducted in Taiwan, Sweden and the United States (US), a pooled rate ratio (RR) for depression in AS was 1.51 (95% CI, 1.28–1.79). This 51% increase in risk was calculated based on studies that report incidence rates within 1 year, 10 years, and 13 years of developing AS. Smoking and lower education were reported to be associated with a higher risk of depression. The literature search for this review was carried out in 2018, therefore missing more recent studies. One large-scale nationwide study from South Korea based on 11,465 newly diagnosed cases of AS between 2010 and 2014 reported that, compared with age- and sex-matched controls, there was a two-fold increased risk of incident depression in patients with AS, even after controlling for potential confounders and comorbidities (adjusted hazard ratio 2.21; 95% CI, 2.06–2.36). Moreover, the cumulative incidence of depression grew over a 6-year period, suggesting that risk of depression increases over time in patients with AS. In this sample, female sex, lower socioeconomic status, and the number of comorbidities were associated with a higher risk of developing depression. Similarly, a nationwide population-based study from Taiwan examined the risk of depression in 2331 patients with AS during a median 6-year follow-up period. The study reported that following AS diagnosis patients had a three-fold increased risk of depression in the first year and two-fold increased risk after ≥5 years.

Regarding the incidence of depression in PsA, four studies were included in a meta-analysis. These studies comprised a total of 28,614 patients with PsA from the US, and assessed annual incidence following PsA diagnosis. The pooled incidence rate ratio for depression was reported to be 1.44 (95% CI, 1.20–1.73), which was independent of PsA severity. The authors observed that, despite increased rates of depression, only 2.4–13.5% of patients with PsA were taking antidepressant medication, suggesting that many PsA patients who have comorbid depression may not be receiving treatment for their depression. Although incidence of depression appears to be elevated in AS and PsA, incidence may be over-estimated in hospital-based samples due to increased surveillance.

**Common risk factors for depression in AS or PsA patients**

Depression is a complex multifactorial disorder with contributions from both environmental and genetic factors. Female sex, exposure to stressful life events in childhood/adulthood, and socioeconomic deprivation are some of the most extensively replicated factors associated with depression. Examples of stressful life events reported to be associated with depression include bereavement, physical, emotional or sexual abuse, relationship breakdown, lack of employment or confiding relationship, and financial problems. At the physiological level, effects of life stressors are possibly mediated by activation of the hypothalamic-pituitary-adrenal (HPA) axis and low-grade systemic inflammation. Stressful life events could be a useful marker for identifying those potentially at risk of depression in clinical settings. History of depression is also a significant risk factor for subsequent depression, which could be another important risk indicator in clinical settings.

The association of stressful life events and depression with depression have also been replicated in patients with AS, axSpA, and psoriasis. For instance, stress and lower household income have been reported to double the risk of depression in axSpA. As mentioned in the previous section, lower socioeconomic status or educational achievement, smoking and number of comorbidities have been reported to be associated with risk of depression in large population studies of AS. A number of comorbidities are common in patients with AS and PsA, including cardiovascular disease, malignancies, gastrointestinal disorders, among others. Many of these increase the subsequent risk of depression, and vice versa. Moreover, multimorbidity increases risk of depression dependent on the number of physical morbidities. Although it is difficult to ascertain whether depression is a result of multimorbidity, AS, or PsA, it is likely multimorbidity increases psychological and immune system stress, and may present potential pathways through which depression and multimorbidity may be linked. In contrast, results regarding association between depression and sex in patients with AS is somewhat mixed; with studies reporting higher risk in females, males, or no difference. Therefore, it is possible that the risk of depression in AS could be relatively similar between the sexes. Although there is limited literature on the link between stress, socioeconomic status and PsA, low socioeconomic status has been found to increase the risk of depression [odds ratio (OR) 1.17, 95% CI 1.08 1.26], anxiety (OR 1.11, 95% CI 1.01 1.23) and mixed...
anxiety/depression (OR 1.32, 95% CI 1.21 1.45) in psoriasis when compared with healthy controls. Furthermore, low socioeconomic status increased the cumulative probability of anxiety and depression between the ages of 40 and 60 years.72

Potential mechanisms of depression in AS or PsA patients

Role of disease-related factors

Disease severity, poor quality of life and particular symptoms of AS such as fatigue and sleep disturbance have been reported to be associated with depression in patients with AS. In one study, for every unit increase in the Bath AS Disease Activity Index (BASDAI; scale 0–10) the risk of depression in patients with AS increased by 30%.60 In another study, although both disease activity (BASDAI) and AS quality of life scores were moderately correlated with depression (r = 0.50 and 0.60, respectively), multivariable linear regression showed that only poor quality of life was independently associated with depression after taking into account both scores.73 However, disease activity could still be an important risk factor, given the magnitude of its correlation with depression (r = 0.50). Although it is apparent there is a relationship between disease activity, quality of life and depression, cross-sectional data such as these are unable to ascertain the direction of association (i.e. whether depression is a cause or consequence of poor quality of life, disease activity). Longitudinal studies are required to address this issue.

Fatigue is a common symptom in AS, with two studies reporting a correlation with depression severity (r ≤ 0.55).74,75 Considering these two studies were based on relatively small samples (80 and 65 cases of AS), the correlation estimates are relatively large and may indicate a significant role of fatigue in depression in patients with AS. Similarly, sleep quality appears to be related to depressive symptoms. In samples of 318 and 80 patients with AS, Spearman’s correlation between sleep problems and depression was reported to be 0.47 and 0.31, respectively.76,77 Despite moderate correlations between disease related factors and depression, it is difficult to ascertain from cross-sectional data whether fatigue, sleep problems, quality of life and/or disease activity are a cause or consequence of depression. This is because depression could cause or exacerbate these factors of AS, or both depression and AS may share pathophysiologic mechanisms that contribute to the development of these symptoms.

Similarly, disease-related factors can also lead to depression in PsA. Although directionality has not been investigated, PsA disease activity is greater in patients with depression and/or anxiety.78 Similar to AS, sleep and fatigue have been reported to be associated with poor quality of life and risk of depression in patients with PsA.30,79,80 Other PsA symptoms may further affect depression risk. For instance, psoriasis has been shown to impair body image.81 Using hierarchical multiple regression, psoriasis severity and a younger age of onset has been associated with anxiety, while negative body image mediated the relationship between the severity of psoriasis and depression.82 Pain could also be a risk factor for depression. In a longitudinal study pain was associated with subsequent development of depression and vice versa in patients with PsA.43

Inflammation as potential shared mechanism for both depression and SpA

Several lines of evidence suggest the potential role of systemic inflammation, a hallmark of SpA and other rheumatological conditions, in the pathogenesis of depression. Autoimmune disease and severe infection are associated with increased risk for subsequent depression, with all 30 autoimmune disorders assessed (including AS and psoriasis) increasing risk.58 Interferon treatment, a potent inducer of innate immune response, leads to development of depression in up to 40% of patients with hepatitis C virus.83 A meta-analysis of cross-sectional studies have consistently reported increased concentrations of C-reactive protein (CRP) and inflammatory cytokines, such as IL-6 and TNF-α in the peripheral blood and cerebrospinal fluid (CSF) of patients with acute depression compared with healthy controls.84–87 Population-based longitudinal studies have reported that elevated circulating IL-6 and CRP levels in childhood are associated with subsequent development or persistence of depressive symptoms in adulthood,88–90 suggesting that inflammation could be a cause, rather than a consequence of depression. Mendelian randomisation studies, which use genetic variants regulating levels/activity of a biomarker as proxies to address the issue of confounding,91 suggest that IL-6 and CRP could be potentially causally related to
depression, rather than these associations being fully attributable to confounding by lifestyle, stress or other factors.92,93

Inflammation appears to be clinically relevant as it is associated with poor antidepressant response.94,95 Evidence from clinical trials also supports a role of inflammation in depression, with recent studies pointing to key roles for inflammatory cytokines such as IL-6 and TNF-α. In cohorts that include depressed but otherwise healthy participants and participants with depression and comorbid osteoarthritis, non-steroidal anti-inflammatory drugs (NSAIDs) given as adjuncts to antidepressants are associated with greater symptomatic improvements compared with antidepressants alone in randomised controlled trials (RCTs).96 More recently, meta-analyses of secondary outcome data from RCTs of cytokine antagonists, including anti-TNF, anti-IL-6/IL-6R, anti-IL-12/23, anti-IL-4/13 and anti-IL-17 drugs in patients with rheumatoid arthritis, inflammatory bowel disease and other chronic inflammatory physical illness have reported that these drugs improve depressive symptoms independently of improvements in physical illness.97,98 Based on seven placebo-controlled studies, there was a moderate effect size (0.40; 95% CI 0.22–0.59) of anti-cytokine treatment on depressive symptoms, with the majority of studies investigating anti-IL-6 and anti-TNF treatments.97 In a subsequent review, similar effects were observed, demonstrating the largest antidepressant effects in anti-IL-6 and anti-IL12/23 drug classes. After controlling for physical health outcomes, a trend remained for anti-IL-6, while anti-IL-12/23 effects remained significant, with both showing only marginal attenuation.98

Currently a number of RCTs are testing the effects of cytokine and/or cytokine receptor antagonists in patients with depression. However, identifying patients most likely to benefit from immunotherapy is likely to be key for the success of future RCTs, as inflammation is unlikely to be relevant for all patients with depression.99 A RCT of infliximab for treatment resistant depression demonstrated treatment response to be associated with higher baseline CRP levels.100 A proof-of-concept double blind RCT of the anti-IL-6R mAb tocilizumab in patients with depression is underway, with subjects selected based upon evidence of inflammation and inflammation-related symptoms.101

Turning to data from patients with AS, the mood improving effects of infliximab is consistent with a potentially shared role of inflammation in pathogenesis of depression, AS and other chronic inflammatory physical illness.102 Sickness behaviour, a response to inflammation in autoimmune disease or infection, is characterised by fatigue, sleep problems, anhedonia, reduced appetite, concentration and motivation, which are also typical symptoms of depression.103 The depression syndrome consists of heterogeneous symptoms. Data from population-based studies suggest that elevated levels of circulating IL-6 and CRP are associated with particular symptoms of depression, such as fatigue, sleep and appetite disturbance, which are akin to sickness behaviour.104,105

Specific biologic pathways involved in the pathologies of depression and SpA show some concurrence. Whilst the pathogenesis of AS, PsA and depression is yet to be fully understood, recent evidence highlights the IL-17/23 pathway as one of the most important cytokine pathways to contribute to AS and PsA.6,106–108 Elevated IL-23 impairs T helper cells, which contributes to the overexpression of IL-17, IL-22, IL-1, IL-6 and TNF. Interestingly, there is evidence of impaired T helper function in depression.109 IL-6, IL-1β, TNF-α and CRP are also among inflammatory markers shown consistently to be elevated in patients with depression.97,110,111 Nuclear factor (NF)-κB is another marker that has been implicated in both AS and depression,112,113 as are inflammasomes.114–116 Production of these inflammatory proteins may be activated by psychological stress through the hypothalamic pituitary adrenal (HPA) axis. The HPA axis stimulates the release of glucocorticoids and catecholamines, initiating inflammasome assembly,109 which in turn leads to the production of IL-1β and other pro-inflammatory cytokines such as IL-18.117

To date, the medical literature has considered the brain as an immune-privileged site, shielded behind the blood-brain barrier. However, current evidence demonstrates a number of pathways through which peripheral inflammation can communicate with the brain. While the exact neurochemical basis of inflammation-induced depression is still being elucidated, current evidence suggests that inflammatory cytokines can influence mood, cognition and behaviour by: (i) decreasing synaptic availability of serotonin by breaking down
tryptophan along the kynurenine pathway, and by increasing presynaptic reuptake of serotonin; (ii) increasing oxidative stress due to production of reactive oxygen and nitrogen species; (iii) increasing synaptic glutamate leading to excitotoxicity; and (iv) decreasing neurotrophic support and hippocampal neurogenesis. See Figure 1, and reviews by Dantzer et al. and Miller and Raison for a more detailed narrative.\(^{23,109}\)

Shared genetic basis for neuropsychiatric and immune disorders
While no data is currently available on a shared genetic basis for depression and AS specifically, emerging evidence indicates a potential shared genetic basis for a number of neuropsychiatric and immunological disorders.\(^{118}\) One study investigating genetic variants associated with psychiatric illnesses (schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder) and autoimmune diseases (Crohn’s disease, ulcerative colitis, multiple sclerosis, psoriasis, RA, SLE and insulin-dependent diabetes mellitus) reported evidence for genetic pleiotropy in 24 out of 35 psychiatric-immune disorder pairs.\(^{118}\) The strongest pleiotropy was observed for schizophrenia-rheumatoid arthritis with MHC region included in the analysis, and schizophrenia-Crohn’s disease with MHC region excluded.\(^{118}\) Using linkage disequilibrium score regression (LDSC) analysis of available genome-wide association studies (GWAS) data, another study reported significant genetic correlations...
between immune-related disorders and several psychiatric disorders including depression. RA was the only rheumatologic condition included in this study, which showed evidence for genetic correlations with bipolar disorder, obsessive compulsive disorder, attention deficit-hyperactivity disorder and smoking behaviour. With further GWAS using larger samples, future studies may shed light on potential shared genetic basis for spondyloarthritis, depression and other psychiatric disorders.

Management of depression in SpA
Depression is a treatable condition with about two-thirds of patients responding to first-line antidepressant treatment. Depression is associated with poor treatment adherence, poor response to biologics, and higher self-reported disease severity in patients with arthritis. Therefore, it is imperative for clinicians to actively assess and treat depression in AS and other rheumatologic conditions rather than seeing depression as an inevitable by-product of arthritis, pain or poor quality of life. Based on prevalence studies discussed earlier, it is likely that about 40% of patients with AS will have some degree of depressive symptoms while moderate to severe depression is likely to be present in about 15% of patients with AS and PsA. Therefore, routine assessment of depression in rheumatology clinics is necessary to identify these patients, and tailor management strategy accordingly based on depression severity and potential risk.

The UK National Institute for Health and Care Excellence (NICE) recommends depression is assessed in patients with RA on an annual basis. However, it is noteworthy that, with the exception of the National Axial Spondyloarthritis Society (NASS), existing international guidelines for AS do not mention depression, despite this being a common problem in these patients. The NASS recommends that patients with AS see their primary care physician for advice if concerned about their mental wellbeing.

Assessment of depression and associated risk
The NICE guidelines on the recognition and management of depression in adults with a chronic physical health problem provides clinicians not trained in psychiatry with useful suggestions for assessment of depressive symptoms, severity and potential risks (see Textbox 1 for summary).

The NICE guidelines recommend using a validated tool to assess depression. A number of validated questionnaires for assessing depression are available, such as the PHQ-9, Beck Depression Inventory-II (BDI-II) and HADS. The PHQ-9 may be particularly useful in rheumatology clinics, as it is a validated, brief, self-report tool widely used to assess depression in clinical and community samples including in UK primary care. Furthermore, it has been reported that people with arthritis respond to items on the PHQ-9 similarly to those without arthritis, despite the inclusion of somatic items in this scale. This nine-item questionnaire assesses depressive symptoms occurring in the past 2 weeks. Each item is rated as not present (0), present several days (1), more than half the days (2), and nearly every day (3), giving a total depression symptom score of 0–27. Using established thresholds, the score can provide useful categories of depression: no depression (score 0–4); mild depression (5–9); moderate depression (10–14); moderately severe depression (15–19); and severe depression (20–27). A PHQ-9 score $\geqslant$ 10 has a sensitivity of 88% and a specificity of 88% for major depression. The BDI-II could also be useful, as similar to PHQ-9, it focuses mainly on cognitive and psychological aspects of depression, unlike the Hamilton Depression Rating Scale (HAM-D), which includes a number of physical symptoms, making assessment of depression in people with physical illness somewhat tricky. HADS is also used commonly as it measures both depression and anxiety, but it lacks any questions covering suicidal ideation, which is needed to inform risk assessment, an important part of assessment of depression according to the NICE guidelines.

Regarding assessment of suicide risk, it is important for clinicians to know that asking about suicide and related behaviours does not increase the risk of suicide. Suicidal ideation is common in the general population and in people with depression. According to the British National Psychiatric Morbidity Survey, a general population-based survey conducted in 2000, nearly one in six individuals had had death wishes or considered suicide, while 4.4% of the study population had attempted suicide at some time. Prevalence of suicidal thoughts in individuals with depression is higher, ranging up to over 60%, Although
suicidal ideation is relatively common, certain features may indicate higher risk of suicide attempt, such as having a plan, past suicide attempt, recent onset, and time spent thinking about suicide. PHQ-9 and some of the other questionnaires mentioned above can be a good starting point for identifying suicidal ideation, followed by further questioning including assessment of aggravating and protective factors, which may help clinicians to gauge the need for referral to specialist services.

**Treatment considerations**

Assessing severity and risk can inform a stepwise approach to treatment of depression taking into account individual patient preference. According to the NICE guidelines on recognition and management of depression in adults, antidepressants are not recommended as a first-line treatment in recent onset, mild depression. Rather, active monitoring, individual guided self-help, cognitive behavioural therapy (CBT) or exercise are preferred. According to recommendations from the Canadian Dermatology-Rheumatology Comorbidity Initiative expert group, optimising treatment for rheumatologic condition may also be helpful for depression, as better disease control has been reported to reduce symptoms of depression in patients with RA, PsA, and psoriasis. Furthermore, a recent systematic review and meta-analysis has reported that anti-cytokine drugs improve depressive symptoms in patients with chronic inflammatory physical illness, such as RA and psoriasis, independently of improving physical illness.

**Textbox 1.** Summary of the NICE guidelines for the recognition and management of depression in adults with a chronic physical health problem. Clinical guideline (CG91), October 2009 (Section 1.3).

| Identification and recognition (Section 1.3.1) |
|------------------------------------------------|
| 1. Be alert to depression, especially those at greater risk. Consider two questions: |
| o during the last month, have you often been bothered by feeling down, depressed or hopeless? |
| o during the last month, have you often been bothered by having little interest or pleasure in doing things? |
| 2. If the answer to either is yes and the clinician is trained, three further questions below should be asked. If not trained, a referral should be made to the appropriate specialist and/or general practitioner. |
| o during the last month, have you often been bothered by feelings of worthlessness? |
| o during the last month, have you often been bothered by poor concentration? |
| o during the last month, have you often been bothered by thoughts of death? |
| A practitioner may also want to review patients’ mental state, associated functional, interpersonal and social difficulties; consider the role of both the chronic physical health problem and prescribed medication in the development or maintenance of depression; and/or ascertain that the optimal treatment for the physical health problem is being provided, seeking specialist advice if necessary. |
| 3. When depression is suspected, consider using a validated measure (for symptoms, functions and/or disability) to inform and evaluate treatment (alternatives provided and suggested for those with communication difficulties). |

| Risk assessment and monitoring (Section 1.3.2) |
|------------------------------------------------|
| 1. If a patient with depression and a chronic physical health problem presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services. |
| 2. Advise patients with depression and a chronic physical health problem of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment for depression. Patient, family, or carer should be vigilant for mood changes, negativity and hopelessness, and suicidal ideation, and to contact their practitioner if concerned. |
| o ensure that the patient knows how to seek help promptly |
| o review treatment if patient develops marked and/or prolonged agitation. |
| 3. If a patient with depression and a chronic physical health problem is assessed to be at risk of suicide: |
| o take into account toxicity in overdose if an antidepressant is prescribed or the patient is taking other medication; if necessary, limit the amount of drug[s] available |
| o consider increasing the level of support, such as more frequent direct or telephone contacts |
| o consider referral to specialist mental health services.
recommended as the first-line treatment, prescribed at a dose likely to be effective after titration, if necessary. Important points to discuss with all patients include choice of drug, utility/availability of non-pharmacological options (e.g. CBT), likely outcome (i.e. gradual relief of symptoms over several weeks), need to continue treatment after resolution of symptoms (e.g. at least 6–9 months after first episode of depression), and risk and nature of discontinuation symptoms.

Although SSRIs are recommended as first-line, use of these drugs in patients with AS and other rheumatologic conditions may be problematic due to increased risk of peptic ulcer and gastrointestinal (GI), uterine, cerebral and perioperative bleeding. A meta-analysis of 42 observational studies reported a significant association between SSRI use and the risk of bleeding (OR=1.41; 95% CI, 1.27–1.57). It is thought that SSRIs deplete platelet serotonin leading to reduced ability to form clots and subsequent increase in the risk of bleeding. Risk factors for bleeding with SSRIs include older age (particularly >65 years), alcohol misuse, coronary artery disease, hypertension, history of GI bleeding, stroke, peptic ulcer, liver disease and medication usage predisposing to bleeding. Therefore, caution should be exercised when prescribing SSRIs for patients taking NSAIDs, aspirin, anticoagulants or corticosteroids, and for patients with a history of gout, asthma, lupus, psoriasis, etc.

The Maudsley prescribing guidelines in psychiatry, based on limited evidence, suggest that risk of bleeding may be lower with non-SSRI antidepressants that have weak or no effect on serotonin reuptake inhibition, such as mirtazapine, lofepramine and nortriptyline, as opposed to highly potent SSRIs such as fluoxetine or sertraline. The Maudsley guidelines also suggest that if SSRI use cannot be avoided, to monitor patients closely and prescribe gastro-protective proton pump inhibitors. Further on drug interaction, SSRIs may increase risk of serotonin syndrome when prescribed with other serotonergic drugs (e.g. tramadol) and electrolyte disturbance on their own and together with diuretics. Toxicity of medications in overdose may need to be considered especially for patients deemed high risk of overdose/suicide.

When to consider psychiatric referral
For community-based patients, the NICE guidelines recommend referral to their primary care physician for further assessment when depression is suspected, if the clinician is not trained/competent to perform this assessment (see Textbox 1). Patients should be informed if referrals to specialist mental health services are made. While for the majority of patients a referral to a general practitioner (GP) is likely to be the appropriate route, specialist psychiatric referral should be considered for more complex or high-risk patients. Such scenarios may include treatment resistance (i.e. failure to respond to two or more antidepressants), bipolar depression (antidepressant may induce mania) or multi-morbidity (e.g. comorbid complex/severe physical illness or other psychiatric disorders such as schizophrenia, anxiety disorder, personality disorder, substance use). In such scenarios, specialist psychiatric input could help to inform specific treatment considerations. Risk of suicide may also require more immediate intervention or more specialised assessment and care.

Pathways to specialist mental health care differ widely depending on area or country. For patients in the community, GPs in the UK are best placed to refer patients to appropriate mental health services as they are aware of local service provision and care pathway arrangements. In hospital settings, referrals to specialist liaison psychiatry services would be most appropriate. Liaison psychiatry provides specialist assessment and advice for management of patients across the range of psychiatric conditions, including depression. Naturally, this enables collaboration between specialists in rheumatology and psychiatry, and the best course of treatment can be mutually determined.

Conclusion
Depression is a major neuropsychiatric disorder, which is common in patients with rheumatological conditions including spondyloarthritis and is associated with poor treatment response and quality of life (see Textbox 2 for summary of key conclusions). Based on meta-analysis, about 40% of patients with AS show some depressive symptoms while moderate/severe depression is present in about 15% of AS and PsA patients. Longitudinal studies indicate that the risk of depression in patients with AS or PsA increases over time. Risk factors for depression in the general population include socioeconomic deprivation and stressful life events such as abuse, relationship breakdown, lack of employment or confiding relationship, and
financial problems. In AS and PsA, there are additional disease-related factors that may increase the risk of depression, such as disease activity, quality of life, sleep and fatigue. Furthermore, accumulating evidence suggests a potential causal role for inflammation in depression, which could be a shared mechanism for these conditions.

Given the strong associations of depression with poor treatment response, disease severity and quality of life in patients with rheumatologic conditions, it is crucial for clinicians in rheumatology services to actively assess and treat depression. Optimal management of depression in AS would be aided by routine assessment of depression using validated tools such as the PHQ-9 questionnaire. While optimising disease control and non-pharmacological interventions such as guided self-help, exercise or psychotherapy is likely to be helpful for mild depression, while antidepressants are recommended for those with moderate/severe depression. Choice of antidepressant requires careful consideration because of potential risk of adverse effects, such as bleeding, from concurrent use of high potency SSRIs and anti-inflammatory drugs.

Referral to specialist mental health services should be considered for more complex or high-risk patients, such as patients with multimorbidity, antidepressant resistance, substance misuse or suicide risk.

Acknowledgements
The authors would like to thank Claire Dibben (Consultant Psychiatrist, Norfolk and Suffolk NHS Foundation Trust) and Cathy Walsh (Consultant Liaison Psychiatrist, Cambridgeshire and Peterborough NHS Foundation Trust) for their helpful advice.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GMK acknowledges funding support from Wellcome Trust (Intermediate Clinical Fellowship; grant code: 201486/Z/16/Z); the MQ: Transforming Mental Health (Data Science Award; grant code: MQDS17/40); the Medical Research Council UK (MICA: Mental Health Data Pathfinder; grant code: MC_PC_17213 and Therapeutic Target Validation in Mental Health; grant code: MR/S037675/1); and the BMA Foundation (J Moultor grant 2019). The MRC grant MC_PC_17213 supports JTP; and the BMA Foundation grant supports EMF. DRJ acknowledges research funding support from the Cambridge Arthritis Research Endeavour (CARE) charity.
References

1. Stolwijk C, van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. *Arthritis Care Res* 2016; 68: 1320–1331.

2. Ogdie A and Weiss P. The epidemiology of psoriatic arthritis. *Physiol Behav* 2015; 41: 545–568.

3. Sieper J, Rudwaleit M, Khan MA, et al. Concepts and epidemiology of spondyloarthritis. *Best Pract Res Clin Rheumatol* 2006; 20: 401–417.

4. Veale DJ and Fearon U. The pathogenesis of psoriatic arthritis. *Lancet* 2018; 391: 2273–2284.

5. Cantini F, Niccoli L, Nannini C, et al. Psoriatic arthritis: a systematic review. *Int J Rheum Dis* 2010; 13: 300–317.

6. Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. *Bone Res* 2019; 7: 1–16.

7. Raychaudhuri SK, Saxena A and Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. *Clin Rheumatol* 2015; 34: 1019–1023.

8. Robinson PC and Benham H. Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. *Intern Med J* 2015; 45: 127–133.

9. Atzeni F, Ventura D, Batticciotto A, et al. Interleukin 6 blockade: tocilizumab in psoriatic arthritis. *J Rheum Dis Suppl* 2012; 89: 97–99.

10. Simone D, Al Mossawi MH and Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. *Rheumatol* 2018; 57: vi4–vi9.

11. Lim GY, Tam WW, Lu Y, et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. *Sci Rep* 2018; 8: 1–10.

12. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Arch Gen Psychiatry* 2005; 62: 593–602.

13. Murray CJL and Lopez AD. Measuring the global burden of disease. *N Engl J Med* 2013; 369: 448–457.

14. World Health Organization. *ICD-10: international statistical classification of diseases and related health problems: tenth revision*. 2nd ed. Geneva, Switzerland: World Health Organization, 2004.

15. Kupfer DJ, Frank E and Wamboff J. Mood disorders: update on prevention of recurrence. In: *Interpersonal factors in the origin and course of affective disorders*. London, England: Gaskell/Royal College of Psychiatrists, 1996, pp.289–302.

16. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. *Am J Psychiatry* 1992; 149: 999–1010.

17. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders, text revision*. 4th ed. Washington, DC: American Psychiatric Association, 2000.

18. Howard DM, Adams MJ, Shirali M, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun* 2018; 9: 1–10.

19. Howard DM, Adams MJ, Clarke T-K, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci* 2019; 22: 343–352.

20. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 2018; 50: 668–681.

21. Li H, Chang H, Song X, et al. Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder. *Neuropsychopharmacol* 2019; 44: 1552–1561.

22. Nemeroff CB. Prevalence and management of treatment-resistant depression. *J Clin Psychiatry* 2007; 68: 17–25.

23. Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; 9: 46–56.

24. Khandaker GM, Dantzer R and Jones PB. Immunopsychiatry: important facts. *Psychol Med* 2017; 47: 2229–2237.

25. Raison CL, Capuron L and Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends Immunol* 2006; 27: 24–31.

26. Dunlop DD, Lyons JS, Manheim LM, et al. Arthritis and heart disease as risk factors.
for major depression: the role of functional limitation. Med Care 2004; 42: 502–511.

27. Stuart MJ and Baune BT. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev 2012; 36: 658–676.

28. Champaneri S, Wand GS, Malhotra SS, et al. Biological basis of depression in adults with diabetes. Curr Diab Rep 2010; 10: 396–405.

29. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol 2013; 52: 2136–2148.

30. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken) 2012; 64: 1593–1601.

31. Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther 2018; 20: 1–9.

32. DiMatteo MR, Lepper HS and Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107.

33. Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for rheumatology biologics register. Rheumatol 2018; 57: 835–843.

34. Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatol 2015; 55: 268–278.

35. Sundquist K, Li X, Hemminki K, et al. Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases: a nationwide study from Sweden. Arch Gen Psychiatry 2008; 65: 501–507.

36. Zhao SS, Radner H, Siebert S, et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology 2019; 58: 1746–1754.

37. Park JY, Howren AM, Zusman EZ, et al. The incidence of depression and anxiety in patients with ankylosing spondylitis: a systematic review and meta-analysis. BMC Rheumatol 2020; 4: 1–8.

38. Kamalaraj N, El-Haddad C, Hay P, et al. Systematic review of depression and anxiety in psoriatic arthritis. Int J Rheum Dis 2019; 22: 967–973.

39. Kang J-H, Chen Y-H and Lin H-C. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010; 69: 1165–1168.

40. Elixhauser A, Steiner C, Harris R, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27.

41. McDonough E, Ayestar R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41: 887–896.

42. Lewison RT, Vallerand IA, Lowerison MW, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol 2017; 137: 828–835.

43. Husted JA, Tom BD, Farewell VT, et al. Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 758–765.

44. Zusman EZ, Howren AM, Park JYE, et al. Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. Epub ahead of print 13 February 2020. DOI: 10.1016/j.semarthrit.2020.02.001.

45. Wu JJ, Penfold RB, Primatessa P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol 2017; 31: 1168–1175.

46. Shen C-C, Hu L-Y, Yang AC, et al. Risk of psychiatric disorders following ankylosing spondylitis: a nationwide population-based retrospective cohort study. J Rheumatol 2016; 43: 625–631.

47. Meesters JJJ, Bremaender A, Bergman S, et al. The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 2014; 16: 1–5.

48. Kilic G, Kilic E and Ozgocmen S. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Medicine (Baltimore) 2014; 93: 1–6.
49. Zou Q, Jiang Y, Mu F, et al. Correlation of axial spondyloarthritis with anxiety and depression. Med Sci Monit 2016; 22: 3202–3208.

50. Park JS, Jang HD, Hong JY, et al. Impact of ankylosing spondylitis on depression: a nationwide cohort study. Sci Rep 2019; 9: 1–6.

51. Musliner KL, Seifuddin F, Judy JA, et al. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry 1995; 152: 833–842.

52. Kendler KS, Kessler RC, Walters EE, et al. Polygenic risk, stressful life events and depressive symptoms in older adults: a polygenic score analysis. Psychiatr Med 2015; 45: 1709–1720.

53. Mandelli L, Petrelli C and Serretti A. The role of specific early trauma in adult depression: a meta-analysis of published literature. Childhood trauma and adult depression. Eur Psychiatry 2015; 30: 665–680.

54. Rai D, Zitko P, Jones K, et al. Country- and individual-level socioeconomic determinants of depression: multilevel cross-national comparison. Br J Psychiatry 2013; 202: 195–203.

55. Shapero BG, Black SK, Liu RT, et al. Stressful life events and depression symptoms: the effect of childhood emotional abuse on stress reactivity. J Clin Psychol 2014; 70: 209–223.

56. McLaughlin KA, Conron KJ, Koenen KC, et al. Childhood adversity, adult stressful life events, and risk of past-year psychiatric disorder: a test of the stress sensitization hypothesis in a population-based sample of adults. Psychol Med 2010; 40: 1647–1658.

57. Heim C, Newport DJ, Mletzko T, et al. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008; 33: 693–710.

58. Benros M, Walof B, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013; 70: 812–820.

59. Kendler KS and Gardner CO. Dependent stressful life events and prior depressive episodes in the prediction of major depression: the problem of causal inference in psychiatric epidemiology. Arch Gen Psychiatry 2010; 67: 1120–1127.

60. Redeker I, Hoffmann F, Callhoff J, et al. Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Ann Rheum Dis 2018; 77: 1017–1024.

61. Jamnitski A, Symmons D, Peters MJL, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211–216.

62. Ahmed N, Prior JA, Chen Y, et al. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 2016; 35: 3069–3073.

63. Ogdie A, Schwartzman S and Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015; 27: 118–126.

64. Walsh JA, Song X, Kim G, et al. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Heal Serv Res 2018; 9: 115–121.

65. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011; 63: 1729–1735.

66. Nas K, Karkuca M, Durmus B, et al. Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis 2015; 18: 873–879.

67. Spiegel D and Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003; 54: 269–282.

68. Hare DL, Toukhsati SR, Johansson P, et al. Depression and cardiovascular disease: a clinical review. Eur Heart J 2014; 35: 1365–1372.

69. Smith DJ, Court H, McLean G, et al. Depression and multimorbidity: a cross-sectional study of 1,751,841 patients in primary care. J Clin Psychiatry 2014; 75: 1202–1208.

70. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37–43.

71. Webers C, Vanhoof L, Leue C, et al. Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Res Ther 2019; 21: 1–10.

72. Tzur Bitan D, Krieger I, Comaneshter D, et al. The association between the socioeconomic status and anxiety-depression comorbidity in patients with psoriasis: a nationwide population-based study. J Eur Acad Dermatol Venereol 2019; 33: 1555–1561.
73. Baysal Ö, Durmuş B, Ersoy Y, et al. Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. *Rheumatol Int* 2011; 31: 795–800.

74. Schneebberger EE, Marengo MF, Dal Pra F, et al. Fatigue assessment and its impact in the quality of life of patients with ankylosing spondylitis. *Clin Rheumatol* 2015; 34: 497–501.

75. Durmus D, Sarisoy G, Alaylı G, et al. Psychiatric symptoms in ankylosing spondylitis: their relationship with disease activity, functional capacity, pain and fatigue. *Compr Psychiatry* 2015; 62: 170–177.

76. Li Y, Zhang S, Zhu J, et al. Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. *Arthritis Res Ther* 2012; 14: R215.

77. Batmaz I, Sarıyıldız MA, Dilek B, et al. Sleep quality and associated factors in ankylosing spondylitis: relationship with disease parameters, psychological status and quality of life. *Rheumatol Int* 2013; 33: 1039–1045.

78. Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. *Clin Rheumatol* 2020; 39: 217–225.

79. Carneiro C, Chaves M, Verardino G, et al. Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. *Clin Cosmet Investig Dermatol* 2017; 10: 155–163.

80. Wu C-Y, Chang Y-T, Juan C-K, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. *Medicine (Baltimore)* 2016; 95: e3816.

81. Khoury LR, Danielsen PL and Skiveren J. Body image altered by psoriasis. A study based on individual interviews and a model for body image. *J Dermatolog Treat* 2014; 25: 2–7.

82. Łakuta P and Przybyła-Basista H. Toward a better understanding of social anxiety and depression in psoriasis patients: the role of determinants, mediators, and moderators. *J Psychosom Res* 2017; 94: 32–38.

83. Lotrich FE. Major depression during interferon-α treatment: vulnerability and prevention. *Dialogues Clin Neurosci* 2009; 11: 417–425.

84. Wang AK and Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. *Schizophr Bull* 2018; 44: 75–83.

85. Howren MB, Lamkin DM and Suls J. Associations of depression with c-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 2009; 71: 171–186.

86. Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. *Brain Behav Immun* 2015; 49: 206–215.

87. Goldsmith D, Rapaport M and Miller B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 2016; 21: 1696–1709.

88. Khandaker GM, Pearson RM, Zammit S, et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study. *JAMA Psychiatry* 2014; 71: 1121–1128.

89. Khandaker GM, Stochl J, Zammit S, et al. Childhood inflammatory markers and intelligence as predictors of subsequent persistent depressive symptoms: a longitudinal cohort study. *Psychol Med* 2018; 48: 1514–1522.

90. Zalli A, Jovanova O, Hoogendijk WJG, et al. Low-grade inflammation predicts persistence of depressive symptoms. *Psychopharmacology (Berl)* 2016; 233: 1669–1678.

91. Smith GD and Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003; 32: 1–22.

92. Khandaker GM, Zuber V, Rees JMB, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* 2020; 25: 1477–1486.

93. Khandaker GM, Zammit S, Burgess S, et al. Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. *Brain Behav Immun* 2018; 69: 264–272.

94. Carvalho LA, Torre JP, Papadopoulos AS, et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. *J Affect Disord* 2013; 148: 136–140.
95. O’Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatr Res* 2007; 41: 326–331.

96. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry* 2014; 71: 1381–1391.

97. Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. *Mol Psychiatry* 2018; 23: 335–343.

98. Wittenberg GM, Stylianou A, Zhang Y, et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. *Mol Psychiatry* 2020; 25: 1275–1285.

99. Osmo EF, Baxter LJ, Lewis G, et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol Med* 2019; 49: 1958–1970.

100. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab in treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry* 2013; 70: 31–41.

101. Khandaker GM, Oltean BP, Kaser M, et al. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. *BMJ Open* 2018; 8: 1–9.

102. Ertelen I, Ozer S, Kiraz S, et al. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. *Rheumatol Int* 2012; 32: 323–330.

103. Dantzer R. Cytokine, sickness behavior, and depression. *Immunol Allergy Clin North Am* 2009; 29: 247–264.

104. Jokela M, Virtanen M, Batty GD, et al. Inflammation and specific symptoms of depression. *JAMA Psychiatry* 2016; 73: 87–88.

105. Chu AL, Stochl J, Lewis G, et al. Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort. *Brain Behav Immun* 2019; 76: 74–81.

106. Hreggvidsdottir HS, Noordenbos T and Baeten DL. Inflammatory pathways in spondyloarthritis. *Mol Immunol* 2014; 57: 28–37.

107. Furst DE and Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. *Arthritis Res Ther* 2019; 21: 1–15.

108. Nograles KE, Brassington RD and Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. *Nat Clin Pract Rheumatol* 2009; 5: 83–91.

109. Miller AH and Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 2016; 16: 22–34.

110. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. * Biol Psychiatry* 2010; 67: 446–457.

111. Lotrich FE. Inflammatory cytokine-associated depression. *Brain Res* 2015; 1617: 113–125.

112. Kim TH, Stone MA, Rahman P, et al. Interleukin 1 and nuclear factor-κB polymorphisms in ankylosing spondylitis in Canada and Korea. *J Rheumatol* 2005; 32: 1907–1910.

113. Felger JC and Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. *Neuroscience* 2013; 246: 199–229.

114. Spel L and Martinon F. Inflammasomes contributing to inflammation in arthritis. *Immunol Rev* 2020; 294: 48–62.

115. Iwata M, Ota KT and Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. *Brain Behav Immun* 2013; 31: 105–114.

116. Alcocer-Gómez E, de Miguel M, Casas-Barquero N, et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. *Brain Behav Immun* 2014; 36: 111–117.

117. Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1 activation platform regulating immune responses and disease pathogenesis. *Nat Immunol* 2016; 17: 446–457.

118. Wang Q, Yang C, Gelernter J, et al. Pervasive pleiotropy between psychiatric disorders and immune disorders revealed by integrative analysis of multiple GWAS. *Hum Genet* 2015; 134: 1195–1209.

119. Tylee DS, Sun J, Hess JL, et al. Genetic correlations among psychiatric and
immune-related phenotypes based on genome-wide association data. *AM J Med Genet B Neuropsychiatr Genet* 2018; 177: 641–657.

120. National Institute for Health and Care Excellence. *Depression in adults with a chronic physical health problem: recognition and management*. London: National Institute for Health and Care Excellence, 2009.

121. Smart KL and Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). *Arthritis Care Res (Hoboken)* 2011; 63(Suppl. 11): S454–S466.

122. Kroenke K, Spitzer RL and Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16: 606–613.

123. Hu J and Ward MM. Screening for depression in arthritis populations: an assessment of differential item functioning in three self-reported questionnaires. *Qual Life Res* 2017; 26: 2507–2517.

124. Dazzi T, Gribble R, Wessely S, et al. Does asking about suicide and related behaviours induce suicidal ideation? What is the evidence? *Psychol Med* 2014; 44: 3361–3363.

125. Bebbington PE, Minot S, Cooper C, et al. Suicidal ideation, self-harm and attempted suicide: results from the British psychiatric morbidity survey 2000. *Eur Psychiatry* 2010; 25: 427–431.

126. Vuorilehto M, Valtonen HM, Melartin T, et al. Method of assessment determines prevalence of suicidal ideation among patients with depression. *Eur Psychiatry* 2014; 29: 338–344.

127. Zisook S, Lesser IM, Lebowitz B, et al. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the combining medications to enhance depression outcomes study. *J Clin Psychiatry* 2011; 72: 1322–1332.

128. Nock MK, Millner AJ, Joiner TE, et al. Risk factors for the transition from suicide ideation to suicide attempt: results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). *J Abnorm Psychol* 2018; 127: 139–149.

129. National Institute for Health and Care Excellence. *Depression in adults: recognition and management*. London: National Institute for Health and Care Excellence, 2009.

130. Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative. *J Rheumatol* 2015; 42: 1767–1780.

131. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. *Pharmacol Res* 2017; 118: 19–32.

132. Taylor DM, Barnes TRE and Young AH. *The maudsley prescribing guidelines in psychiatry*. 13th ed. Newark: Wiley-Blackwell, 2018.